arrow_back Back to App

Drug Advertising Restrictions: New Rules for Pharmaceutical Companies

New regulations limit direct-to-consumer drug advertising for the first three years after a drug's approval. This aims to ensure citizens receive accurate information about medications and that companies do not promote them prematurely before full safety and efficacy data are available. This impacts how we learn about new drugs and can enhance our safety.
Key points
Pharmaceutical companies cannot advertise new drugs directly to consumers for the first three years after approval.
Early advertising may be allowed if the Secretary of Health determines it has a positive public health value.
The Secretary of Health can prohibit drug advertising if serious negative health effects are found after market release.
These rules aim to protect public health by restricting early, potentially incomplete, drug advertising.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_S_483
Sponsor: Sen. King, Angus S., Jr. [I-ME]
Process start date: 2025-02-06
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Responsibility in Drug Advertising Act of 2025

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_S_483.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2025-02-06.

What are the main provisions?

Key points include:

  • Pharmaceutical companies cannot advertise new drugs directly to consumers for the first three years after approval.
  • Early advertising may be allowed if the Secretary of Health determines it has a positive public health value.
  • The Secretary of Health can prohibit drug advertising if serious negative health effects are found after market release.
  • These rules aim to protect public health by restricting early, potentially incomplete, drug advertising.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. King, Angus S., Jr. [I-ME].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

CATEGORIES

Health